CA3109734A1 - Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide - Google Patents

Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide Download PDF

Info

Publication number
CA3109734A1
CA3109734A1 CA3109734A CA3109734A CA3109734A1 CA 3109734 A1 CA3109734 A1 CA 3109734A1 CA 3109734 A CA3109734 A CA 3109734A CA 3109734 A CA3109734 A CA 3109734A CA 3109734 A1 CA3109734 A1 CA 3109734A1
Authority
CA
Canada
Prior art keywords
compound
formula
salt
vii
organic phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3109734A
Other languages
English (en)
French (fr)
Inventor
Paul Allen Bethel
Lai Chun Chan
Katie Grace Cooper
Robert John Cox
Michael David Golden
Shaun Alan Hughes
Lucinda Victoria Jackson
Kirsty Jane Millard
Andrew John Phillips
Alexander James Telford
Jerry Evarts
Michael Joseph Lawler
Remy E. J. N. Litjens
Peter Johannes Servaas Savio Van Eijk
Mathilda Maria Henrica Verstappen
Frank L. M. Vos
Eric Jurrien Zijp
Qiu JUNYING
Angang WANG
Rustam Ferdinand Garrey
David Allen Short
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acerta Pharma BV
Original Assignee
Acerta Pharma BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acerta Pharma BV filed Critical Acerta Pharma BV
Publication of CA3109734A1 publication Critical patent/CA3109734A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CA3109734A 2018-08-29 2019-08-28 Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide Pending CA3109734A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862724228P 2018-08-29 2018-08-29
US62/724,228 2018-08-29
PCT/EP2019/072991 WO2020043787A1 (en) 2018-08-29 2019-08-28 Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide

Publications (1)

Publication Number Publication Date
CA3109734A1 true CA3109734A1 (en) 2020-03-05

Family

ID=67928802

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3109734A Pending CA3109734A1 (en) 2018-08-29 2019-08-28 Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide

Country Status (16)

Country Link
US (3) US12024520B2 (cg-RX-API-DMAC10.html)
EP (1) EP3844149A1 (cg-RX-API-DMAC10.html)
JP (3) JP7439095B2 (cg-RX-API-DMAC10.html)
KR (2) KR20250119664A (cg-RX-API-DMAC10.html)
CN (2) CN112638878B (cg-RX-API-DMAC10.html)
AU (4) AU2019332882B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021003480A2 (cg-RX-API-DMAC10.html)
CA (1) CA3109734A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021003676A2 (cg-RX-API-DMAC10.html)
EA (1) EA202190557A1 (cg-RX-API-DMAC10.html)
IL (3) IL281025B2 (cg-RX-API-DMAC10.html)
MA (1) MA53485A (cg-RX-API-DMAC10.html)
MX (2) MX2021002246A (cg-RX-API-DMAC10.html)
MY (1) MY206899A (cg-RX-API-DMAC10.html)
WO (1) WO2020043787A1 (cg-RX-API-DMAC10.html)
ZA (2) ZA202306381B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250119664A (ko) * 2018-08-29 2025-08-07 아세르타 파마. 비.브이. 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의제조 공정
EP3947386A1 (en) * 2019-03-27 2022-02-09 Assia Chemical Industries Ltd Solid state forms of acalabrutinib
DK4054582T3 (da) 2019-11-04 2025-12-01 Astrazeneca Ab Terapeutiske kombinationer af acalabrutinib og capivasertib til behandling af b-celle-maligniteter
CR20230018A (es) 2020-06-19 2023-04-11 Acerta Pharma Bv Formas farmacéuticas de maleato de acalabrutinib

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2372694T3 (es) 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
EP2139487B1 (en) 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US8362249B2 (en) 2009-04-27 2013-01-29 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
US8658794B2 (en) 2010-02-08 2014-02-25 Merck Sharp & Dohme B.V. 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof
CN103889987B (zh) * 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2014113942A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
MX362181B (es) 2013-02-19 2019-01-08 Ono Pharmaceutical Co Compuesto inhibidor de cinasa del receptor de tropomiosina (trk).
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
WO2016128912A1 (en) 2015-02-12 2016-08-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
IL293821A (en) 2015-07-02 2022-08-01 Acerta Pharma Bv Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide
WO2017077507A1 (en) * 2015-11-06 2017-05-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of bruton's tyrosine kinase
CN107056786B (zh) 2016-10-14 2019-05-07 苏州明锐医药科技有限公司 阿卡替尼的制备方法
ES2856248T3 (es) 2016-12-21 2021-09-27 Acerta Pharma Bv Inhibidores de imidazopirazina de la tirosina quinasa de Bruton
WO2018115965A1 (en) * 2016-12-23 2018-06-28 Acerta Pharma Bv Solid forms of imidazopyrazine compounds
CN106588937B (zh) 2017-01-16 2018-09-21 东莞市真兴贝特医药技术有限公司 咪唑并吡嗪类化合物及其制备方法和应用
US10899770B2 (en) 2017-02-20 2021-01-26 Hangzhou Solipharma Co., Ltd. Crystal form of ACP-196 salt and preparation method, pharmaceutical composition, and use thereof
US10800787B2 (en) 2017-04-20 2020-10-13 Apotex Inc. Process for the preparation of acalabrutinib
CN107522701B (zh) 2017-09-01 2019-11-08 苏州富士莱医药股份有限公司 一种治疗慢性淋巴细胞白血病的BTK抑制剂Acalabrutinib的合成方法
US11161851B2 (en) 2017-11-06 2021-11-02 Suzhou Pengxu Pharmatech Co. Ltd. Processes to produce acalabrutinib
CN108250186B (zh) * 2018-02-07 2020-01-14 杭州科巢生物科技有限公司 Acalabrutinib及其中间体的合成方法
WO2019239374A1 (en) 2018-06-13 2019-12-19 Acerta Pharma B.V. Imidazopyrazine inhibitors of interleukin-2-inducible t-cell kinase
KR20250119664A (ko) * 2018-08-29 2025-08-07 아세르타 파마. 비.브이. 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의제조 공정
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法

Also Published As

Publication number Publication date
MX2023011692A (es) 2023-10-19
US20240317766A1 (en) 2024-09-26
JP2026021364A (ja) 2026-02-10
KR20210053304A (ko) 2021-05-11
AU2023204660A1 (en) 2023-08-03
IL322382A (en) 2025-09-01
AU2023204660B2 (en) 2024-01-25
WO2020043787A1 (en) 2020-03-05
IL281025B1 (en) 2024-08-01
JP2024037935A (ja) 2024-03-19
US12448387B2 (en) 2025-10-21
AU2022200828B2 (en) 2023-05-25
KR102842131B1 (ko) 2025-08-04
CN112638878A (zh) 2021-04-09
JP2021535220A (ja) 2021-12-16
CN112638878B (zh) 2025-07-22
KR20250119664A (ko) 2025-08-07
IL281025A (en) 2021-04-29
JP7829541B2 (ja) 2026-03-13
AU2024202290A1 (en) 2024-05-02
US12024520B2 (en) 2024-07-02
MX2021002246A (es) 2021-05-27
IL312413A (en) 2024-06-01
CN120904205A (zh) 2025-11-07
US20260109701A1 (en) 2026-04-23
MA53485A (fr) 2021-12-08
IL312413B1 (en) 2025-09-01
ZA202306381B (en) 2024-11-27
ZA202409391B (en) 2025-04-30
EA202190557A1 (ru) 2021-07-13
CO2021003676A2 (es) 2021-04-08
AU2022200828A1 (en) 2022-03-03
EP3844149A1 (en) 2021-07-07
JP7439095B2 (ja) 2024-02-27
BR112021003480A2 (pt) 2021-05-18
AU2019332882A1 (en) 2021-04-22
AU2019332882B2 (en) 2022-01-27
IL312413B2 (en) 2026-01-01
MY206899A (en) 2025-01-13
US20220127270A1 (en) 2022-04-28
IL281025B2 (en) 2024-12-01

Similar Documents

Publication Publication Date Title
AU2023204660B2 (en) Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide
JP7042175B2 (ja) 3-(イミダゾ[1,2-b]ピリダジン-3-イルエチニル)-4-メチル-N-{4-[(4-メチルピペラジン-1-イル)メチル]-3-(トリフルオロメチル)フェニル}ベンズアミドおよびその一塩酸塩の結晶形
CA3243870A1 (en) NLRP3 INHIBITORS
EP2556074B1 (en) Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it
WO2017069173A1 (ja) 複素環化合物
JP2026021408A (ja) Gabaa陽性アロステリック調節因子化合物、作成方法、およびその使用
AU2016214802B2 (en) Diaza-benzofluoranthrene compounds
IL312472A (en) Evaluation system, evaluation method and evaluation software
EA043329B1 (ru) СПОСОБЫ ПОЛУЧЕНИЯ 4-{8-АМИНО-3-[(2S)-1-(БУТ-2-ИНОЛ)ПИРРОЛИДИН-2-ИЛ]ИМИДАЗО[1,5-a]ПИРАЗИН-1-ИЛ}-N-(ПИРИДИН-2-ИЛ)БЕНЗАМИДА
HK40041702A (en) Processes for the preparation of acalabrutinib
EA049170B1 (ru) СПОСОБ ПОЛУЧЕНИЯ 4-{8-АМИНО-3-[(2S)-2-ПИРРОЛИДИНИЛ]ИМИДАЗО[1,5-a]ПИРАЗИН-1-ИЛ}-N-(2-ПИРИДИНИЛ)БЕНЗАМИДА
HK40041702B (en) Processes for the preparation of acalabrutinib
US20210188823A1 (en) Method for Producing Diarylpyridine Derivatives
WO2024059220A2 (en) 6,5 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same
WO2016127965A1 (en) Solid forms of dolutegravir salts and a method of their preparation
WO2025009477A1 (ja) 3-メチル-1,2,4-チアジアゾール-5-カルボヒドラジドの新規製造方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240412

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250520

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250709

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250714

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250724

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250728

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250728

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260601

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260602